EP3831375 - RAPID RELIEF OF MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 19.08.2022 Database last updated on 15.11.2024 | |
Former | Request for examination was made Status updated on 10.12.2021 | ||
Former | The application has been published Status updated on 07.05.2021 | Most recent event Tooltip | 30.08.2024 | Change: Appeal number | Applicant(s) | For all designated states Civitas Therapeutics, Inc. 420 Saw Mill River Road Ardsley, NY 10502 / US | [2021/48] |
Former [2021/23] | For all designated states Civitas Therapeutics, Inc. 190 Everett Ave. Chelsea, MA 02150 / US | Inventor(s) | 01 /
BATYCKY, Richard P. 11 Madison Avenue Newton, MA 02460 / US | 02 /
FREED, Martin 15 Standish Circle Wellesley MA, 02481 / US | 03 /
LIPP, Michael M. 45a Flanagan Drive Framingham, MA 01710 / US | [2021/23] | Representative(s) | Lee, Nicholas John, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2021/23] | Application number, filing date | 21150770.2 | 21.04.2014 | [2021/23] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3831375 | Date: | 09.06.2021 | Language: | EN | [2021/23] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 22.04.2021 | Classification | IPC: | A61K31/198, A61K9/14, A61K9/48, A61P25/16 | [2021/23] | CPC: |
A61K31/198 (EP,IL,KR,US);
A61K9/14 (RU);
A61K9/0075 (EP,IL,KR,US);
A61P25/16 (EP,IL,RU)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/02] |
Former [2021/23] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | SCHNELLE LINDERUNG VON MOTORISCHEN FLUKTUATIONEN BEI MORBUS PARKINSON | [2021/23] | English: | RAPID RELIEF OF MOTOR FLUCTUATIONS IN PARKINSON'S DISEASE | [2021/23] | French: | SOULAGEMENT RAPIDE DES FLUCTUATIONS MOTRICES DANS LA MALADIE DE PARKINSON | [2021/23] | Examination procedure | 07.12.2021 | Amendment by applicant (claims and/or description) | 07.12.2021 | Examination requested [2022/02] | 07.12.2021 | Date on which the examining division has become responsible | 19.08.2022 | Despatch of a communication from the examining division (Time limit: M06) | 22.03.2023 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 01.06.2023 | Reply to a communication from the examining division | 04.04.2024 | Cancellation of oral proceeding that was planned for 04.06.2024 | 23.04.2024 | Despatch of communication that the application is refused, reason: substantive examination {1} | 04.06.2024 | Date of oral proceedings (cancelled) | Appeal following examination | 21.06.2024 | Appeal received No. T1120/24 | 21.06.2024 | Payment of appeal fee | 23.08.2024 | Statement of grounds filed | Parent application(s) Tooltip | EP14889874.5 / EP3134077 | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 01.06.2023 | Request for further processing filed | 01.06.2023 | Full payment received (date of receipt of payment) Request granted | 12.06.2023 | Decision despatched | Fees paid | Renewal fee | 30.03.2021 | Renewal fee patent year 03 | 30.03.2021 | Renewal fee patent year 04 | 30.03.2021 | Renewal fee patent year 05 | 30.03.2021 | Renewal fee patent year 06 | 30.03.2021 | Renewal fee patent year 07 | 15.04.2021 | Renewal fee patent year 08 | 28.03.2022 | Renewal fee patent year 09 | 27.04.2023 | Renewal fee patent year 10 | 12.04.2024 | Renewal fee patent year 11 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]GB2454480 (VECTURA GROUP PLC [GB]) [Y] 1-8 * page 4, line 30 - page 5, line 2 * * page 5, lines 16-21 * * page 9, lines 15-27 * * page 10, lines 20-26 * * page 34, lines 29-31 * * page 37, lines 11-17 * * claims 1, 3, 4, 10, 14, 18 *; | [Y]US8404276 (JACKSON BLAIR [US], et al) [Y] 1-8 * column 5; tables 1, 2 * * column 16, lines 60-64 * * column 17; example 4 * * claims 7-12 *; | [T]WO2014066208 (CIVITAS THERAPEUTICS INC [US]) [T] * page 13, lines 11-15 * * page 29, line 15 - page 20, line 29 * * claim 32 ** figure 8 *; | [Y] - Anonymous, "Inhaled Levodopa as a Treatment for Intermittent Motor Fluctuations in Parkinson's Disease", (20140301), pages 1 - 2, URL: https://www.michaeljfox.org/foundation/grant-detail.php?grant_id=1176, (20171109), XP055423106 [Y] 1-8 * the whole document * | [A] - MARTIN FREED ET AL, "Rapid Levodopa Augmentation Following Inhaled CVT-301 Results in Rapid Improvement in Motor Response When Administered to PD Patients in the OFF State (S7,007)", NEURO, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 82, no. 10, ISSN 0028-3878, (20140408), pages 1 - 2, (20140408), XP008184053 [A] 1-8 * the whole document * | [Y] - Nate Herpich, "A Breath of Relief: Inhaled Formulation of Levodopa Reduces 'Off' Periods in People with Parkinson's", Foxfeed Blog, (20130419), pages 1 - 2, URL: https://www.michaeljfox.org/foundation/news-detail.php?breath-of-relief-inhaled-formulation-of-levodopa-reduces-off-periods-in-people-with-parkinson, (20171109), XP055423098 [Y] 1-8 * the whole document * | [Y] - Anonymous, "NCT01617135 on 2013_06_13: Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes", ClinicalTrials.gov Archive, (20130613), pages 1 - 3, URL: https://clinicaltrials.gov/archive/NCT01617135/2013_06_13, (20171109), XP055423097 [Y] 1-8 * the whole document * | [AP] - Anonymous, "CVT-inhaled levodopa for the treatment of Parkinson's disease - Civitas Therapeutics Announces Positive Phase 2b Results for CVT-301, Inhaled Levodopa for the Treatment of Parkinson's Disease", (20140428), pages 1 - 7, URL: http://www.fh-partners.com/news-entries/2014/4/28/civitas-therapeutics-announces-positive-phase-2b-results-for-cvt-301-inhaled-levodopa-for-the-treatment-of-parkinsons-disease, (20171109), XP055423101 [AP] 1-8 * page 1, paragraph l - page 2, paragraph 3 * * page 2, paragraph l - page 3, paragraph 2 * | by applicant | US6254854 | US6514482 | US6858199 | US7556798 | USRE43711E | US8496002 | - KAWAGUCHI, H. et al., Biomaterials, (19860000), vol. 7, pages 61 - 66 | - KRENIS, L.J.STRAUSS, B., Proc. Soc. Exp. Med., (19610000), vol. 107, pages 748 - 750 | - RUDT, S.MULLER, R.H., J. Contr. Rel., (19920000), vol. 22, pages 263 - 272 | - EDWARDS, D.A., J. Aerosol Sci., (19950000), vol. 26, pages 293 - 317 | - "Physico-chemical principles in aerosol delivery", GONDA, I, Topics in Pharmaceutical Sciences, Medpharm Scientific Publishers, (19910000), pages 95 - 117 | - HEYDER, J. et al., J. Aerosol Sci., (19860000), vol. 17, pages 811 - 825 | - VISSER, J., Powder Technology, vol. 58, pages 1 - 10 | - SHULMAN et al., Arch Neurol, (20100100), vol. 67 |